Search Results - "Wierda, J. M.K.H."

Biphasic EEG changes in relation to loss of consciousness during induction with thiopental, propofol, etomidate, midazolam or sevoflurane by Kuizenga, K, Wierda, J.M.K.H., Kalkman, C.J.

“…The time course of four EEG effect variables, amplitude in the 2–5 Hz and in the 11–15 Hz band, spectral edge frequency 95% (SEF95), and bispectral index…”
Get full text

Urinary, biliary and faecal excretion of rocuronium in humans by Proost, J.H., Eriksson, L.I., Mirakhur, R.K., Roest, G., Wierda, J.M.K.H.

“…The excretion of rocuronium and its potential metabolites was studied in 38 anaesthetized patients, ASA I–III and 21–69 yr old. Rocuronium bromide was…”
Get full text

Assessment of the clinical relevance of quantitative sensory testing with Von Frey monofilaments in patients with allodynia and neuropathic pain. A pilot study by Keizer, D., van Wijhe, M., Post, W. J., Uges, D. R. A., Wierda, J. M. K. H.

“…BACKGROUND:Allodynia is a common and disabling symptom in many patients with neuropathic pain. Whereas quantification of pain mostly depends on subjective pain…”
Get full text

Good Clinical Research Practice guidelines and PK-PD modelling without twitch stabilisation by Eleveld, D. J., Proost, J. H., De Haes, A., Wierda, J. M. K. H.

Get full text

Is time to peak effect of neuromuscular blocking agents dependent on dose? Testing the concept of buffered diffusion by Proost, J. H., Houwertjes, M. C., Wierda, J. M. K. H.

“…BACKGROUND AND OBJECTIVESFor neuromuscular blocking agents, an inverse relationship between potency and time to peak effect has been observed. To test the…”
Get full text

Model to describe the degree of twitch potentiation during neuromuscular monitoring by Eleveld, D.J., Kopman, A.F., Proost, J.H., Wierda, J.M.K.H.

“…Neuromuscular block is estimated by comparing the evoked peak twitch with a control value measured in the absence of neuromuscular block. In practice, this…”
Get full text

Rapacuronium 2.0 or 2.5 mg kg(-1) for rapid-sequence induction: Comparison with succinylcholine 1.0 mg kg(-1) by Blobner, M, Mirakhur, R K, J M K H Wierda, Wright, P M C

“…The purpose of this nine-centre study in 602 patients was to show that the frequency of acceptable intubating conditions after rapacuronium 2.0 or 2.5 mg kg-1…”
Get full text

Reversal of rocuronium induced neuromuscular block by Org 25969: pharmacokinetics: A-576 by Vermeyen, K. M., Sparr, H. J., Beaufort, A. M., Houwing, N. S., Saldien, V., Velik-Salchner, C., Wierda, J. M.K.H.

Get full text

Prolonged closed‐loop control of muscle relaxation using rocuronium by De Haes, A, Eleveld, D J, Wierda, J M K H

Get full text

Time Course of Action and Endotracheal Intubating Conditions of Org 9487, a New Short-Acting Steroidal Muscle Relaxant; A Comparison with Succinylcholine by Wierda, J. Mark K. H., van den Broek, Lambertus, Proost, Johannes H., Verbaan, Bart W., Hennis, Pim J.

“…In a randomized study, we evaluated lag time (time from the end of injection of muscle relaxant until the first depression of the train-of-four response…”
Get full text

Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure by Cooper, R A, Maddineni, V R, Mirakhur, R K, Wierda, J M, Brady, M, Fitzpatrick, K T

“…We have studied the onset and duration of action and pharmacokinetics of rocuronium bromide (Org 9426) during anaesthesia with nitrous oxide, fentanyl and…”
Get more information

Rapacuronium by Wierda, J M

“…Rapacuronium (Org 9487; ED90 = 1 mg x kg(-1)) is a new, low potency, short-acting, non-depolarizing neuromuscular blocking agent. An intubating dose of…”
Get full text

Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients by Sparr, H J, Wierda, J M, Proost, J H, Keller, C, Khuenl-Brady, K S

“…We have studied dose requirements, recovery times and pharmacokinetics of rocuronium in 32 intensive care patients. After an initial dose of 50 mg, rocuronium…”
Get full text

Transient nerve damage following intubation for trans-sphenoidal hypophysectomy by Evers, K A, Eindhoven, G B, Wierda, J M

“…To describe a case of transient lingual and hypoglossal nerve damage following intubation for a trans-sphenoidal hypophysectomy. A 56-yr-old acromegalic man…”
Get full text

Clinical observations on the neuromuscular blocking action of Org 9426, a new steroidal non-depolarizing agent by Wierda, J M, de Wit, A P, Kuizenga, K, Agoston, S

“…The neuromuscular blocking effects of Org 9426, the 2-morpholino, 16-allyl-pyrrolidino derivative of the 3-desacetoxy analogue of vecuronium have been…”
Get more information

Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia by McCoy, E P, Mirakhur, R K, Maddineni, V R, Wierda, J M, Proost, J H

“…We have studied the pharmacokinetics of a single bolus of rocuronium (Org 9426), followed by an infusion, in eight patients during anaesthesia with halothane…”
Get full text

Intubating conditions and onset of neuromuscular block of rocuronium (Org 9426); a comparison with suxamethonium by Huizinga, A C, Vandenbrom, R H, Wierda, J M, Hommes, F D, Hennis, P J

“…The intubating conditions and neuromuscular blocking profile following 600 micrograms.kg-1 rocuronium (Org 9426) have been investigated in patients under…”
Get more information

Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent by van den Broek, L, Wierda, J M, Smeulers, N J, Proost, J H

“…We have evaluated in 10 anaesthetized patients the time course of action, infusion requirements, reversibility and pharmacokinetics of Org 9487. Org 9487 was…”
Get more information

Post-sucdnylcholine muscle pain and smoking by Nigrovic, V., Wierda, J. M. K. H.

Get full text

Current developments in anaesthesia and neuromuscular transmission by Wierda, J M, Mirakhur, R K

Get more information